Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
Evidence dashboardStudies since 2007Updated Jul 31, 2026
LiraglutideClinical Trials.
A source-linked view of every Liraglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 75
- Recruiting
- 24
- Completed
- 30
- Terminated
- 2
- Results posted
- 12
- Average enrollment
- 369
- Countries
- 32
- Highest phase
- Phase 4
Largest indexed study
23,280,000 participants · NCT07188545 →Developer / research origin
Novo Nordisk
Evidence summary
Activity is not efficacy.
Liraglutide appears in 75 indexed studies: 24 recruiting, 30 completed and 12 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Liraglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
4Moving Biotech · Knee Osteoarthritis · Synovitis of Knee
Phase 2
Active, not recruiting
129
2026-07
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Phase 1
Recruiting
71
2026-07
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Novo Nordisk · Obesity
Phase 3
Active, not recruiting
78
2026-07
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Indiana University · Obesity
Not applicable
Enrolling by invitation
125,000
2026-06
Showing 6 of 41 studies
NCT IDStudyPhase / statusEnrollmentUpdated
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Type 2 Diabetes Mellitus · Mild Cognitive Impairment
Not applicable
Completed
396
2026-07
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
West China Hospital · Alzheimer Disease · Diabetes Mellitus Type 2
Not applicable
Completed
213,891
2026-07
Adiponectin in Patients With Metabolic Disorders
Moscow Regional Research and Clinical Institute (MONIKI) · Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) · Type 2 Diabetes Mellitus (T2DM)
Not applicable
Completed
130
2026-04
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients
Novo Nordisk · Obesity
Not applicable
Completed
27
2026-04
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Beni-Suef University · Polycystic Ovary
Phase 3
Completed
150
2026-03
Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
Göteborg University · Obesity (Disorder) · Child Obesity
Not applicable
Completed
128
2026-02
Showing 6 of 30 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
University of Chicago · Multiple Sclerosis · Long COVID
Early Phase 1
Suspended
30
2026-03
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes
Centre Hospitalier Universitaire Dijon · Type 2 Diabetes · Overweight
Phase 4
Terminated
48
2026-02
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Centre Hospitalier Universitaire Dijon · Type 2 Diabetes
Phase 4
Terminated
127
2026-02
Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity
University of California, Los Angeles · Dyspnea · Quality of Life
Phase 4
Withdrawn
0
2025-02
Full study index
Search Liraglutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
75 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 39043396 ↗Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024 Jul 23;386:q1645. doi: 10.1136/bmj.q1645. No abstract available.Linked from NCT07702461PMID 33239350 ↗Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, Carty C, Chaput JP, Chastin S, Chou R, Dempsey PC, DiPietro L, Ekelund U, Firth J, Friedenreich CM, Garcia L, Gichu M, Jago R, Katzmarzyk PT, Lambert E, Leitzmann M, Milton K, Ortega FB, Ranasinghe C, Stamatakis E, Tiedemann A, Troiano RP, van der Ploeg HP, Wari V, Willumsen JF. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020 Dec;54(24):1451-1462. doi: 10.1136/bjsports-2020-102955.Linked from NCT07702461PMID 41843416 ↗Currier BS, D'Souza AC, Singh MAF, Lowisz CV, Rawson ES, Schoenfeld BJ, Smith-Ryan AE, Steen JP, Thomas GA, Triplett NT, Washington TA, Werner TJ, Phillips SM. American College of Sports Medicine Position Stand. Resistance Training Prescription for Muscle Function, Hypertrophy, and Physical Performance in Healthy Adults: An Overview of Reviews. Med Sci Sports Exerc. 2026 Apr 1;58(4):851-872. doi: 10.1249/MSS.0000000000003897. Epub 2026 Mar 5.Linked from NCT07702461PMID 36841762 ↗Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023 Feb 25;22(1):41. doi: 10.1186/s12933-023-01765-z.Linked from NCT07702461PMID 38629387 ↗Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother. 2024 Apr;25(5):611-619. doi: 10.1080/14656566.2024.2343092. Epub 2024 Apr 18.Linked from NCT07702461PMID 38937282 ↗Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.Linked from NCT07702461PMID 35237446 ↗Shakespear-Druery J, De Cocker K, Biddle SJH, Bennie J. Muscle-Strengthening Exercise Questionnaire (MSEQ): an assessment of concurrent validity and test-retest reliability. BMJ Open Sport Exerc Med. 2022 Feb 14;8(1):e001225. doi: 10.1136/bmjsem-2021-001225. eCollection 2022.Linked from NCT07702461PMID 31221697 ↗Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, Zhang W, Zhu D, Bi Y. Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. Diabetes Care. 2019 Jul;42(7):1274-1283. doi: 10.2337/dc18-2584. Epub 2019 May 21.Linked from NCT05313529
Related pages
Keep researching Liraglutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.